Biomarkers and Personalized Medicine
12.2K views | +0 today
Follow
Biomarkers and Personalized Medicine
Sharing relevant articles on advancements in personalized medicine
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Scooped by Brian Shields
Scoop.it!

FDA approves KRAS gene mutation test for colorectal cancer - News-Medical.net

FDA approves KRAS gene mutation test for colorectal cancer

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

DNA Blood Test Detects Cancer Resistance Using Inostics ... - Manufacturing Digital (press release)

DNA Blood Test Detects Cancer Resistance Using Inostics ...Manufacturing Digital (press release)Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Biomarker panel for early colon cancer diagnosis identified - Cordis News

Biomarker panel for early colon cancer diagnosis identifiedCordis NewsThis is a mathematical model that uses a set of biomarker expression patterns to objectively diagnose colon cancer.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Cetuximab, brivanib failed to extend OS in metastatic colorectal carcinoma - HemOncToday

Cetuximab, brivanib failed to extend OS in metastatic colorectal carcinoma - HemOncToday | Biomarkers and Personalized Medicine | Scoop.it

Cetuximab, brivanib failed to extend OS in metastatic colorectal carcinoma— Despite improvements in PFS and objective response, the combination of cetuximab and brivanib alaninate did not improve survival for patients with...

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Gene mutation and resistance to chemotherapy in colorectal cancer

Gene mutation and resistance to chemotherapy in colorectal cancer | Biomarkers and Personalized Medicine | Scoop.it
This week’s New England Journal of Medicine (NEJM) contained a fascinating article on how a specific gene mutation known as Transcription factor AP-2 epsilon, TFAP2E–DKK4, appears to be responsible for inducing at least some of the resistance to...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

PLoS ONE: Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

PLoS ONE: Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases | Biomarkers and Personalized Medicine | Scoop.it

"In this study, PDTT xenograft models of colon carcinoma with lymphatic and hepatic metastasis have been successfully established. They provide appropriate models for testing of novel molecularly targeted agents..."

 
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

The elusive mystery of KRAS and EGFR inhibitors in colorectal cancer | Pharma Strategy Blog

Evolution of the biology of metastatic colorectal cancer and the impact of KRAS, BRAF and PI3K on the effectiveness of EGFR inhibitors...
 
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Novel Drug TAS-102 Makes Headway in Refractory Colorectal Cancer : IMNG Oncology Report

Novel Drug TAS-102 Makes Headway in Refractory Colorectal Cancer : IMNG Oncology Report | Biomarkers and Personalized Medicine | Scoop.it
STOCKHOLM – The experimental cytotoxic agent TAS-102 significantly reduced the risk of death in a placebo-controlled phase II trial of patients with metastatic colorectal cancer refractory to current treatments.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Medical News: ECCO-ESMO: VEGF Blocker Boosts Survival in Colon Cancer - in Meeting Coverage, ECCO-ESMO from MedPage Today

Medical News: ECCO-ESMO: VEGF Blocker Boosts Survival in Colon Cancer - in Meeting Coverage, ECCO-ESMO from MedPage Today | Biomarkers and Personalized Medicine | Scoop.it
STOCKHOLM -- Patients who've undergone treatment for metastatic colorectal cancer had statistically significant and clinically meaningful improvement in survival when also given a multitargeted angi...
more...
No comment yet.
Rescooped by Brian Shields from Biomarker
Scoop.it!

Oncogene - SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis

Oncogene - SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis | Biomarkers and Personalized Medicine | Scoop.it
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. (Early detection #epigenetic biomarker for #coloncancer.

Via Thierry Sornasse
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Clinical Oncology News - All KRAS Mutations Are Not Created Equal

Clinical Oncology News - All KRAS Mutations Are Not Created Equal | Biomarkers and Personalized Medicine | Scoop.it

Chicago—Tumor KRAS mutation status appears to have a far more complex effect on response to cetuximab in patients with metastatic colorectal cancer (mCRC) than previously thought.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer

Food and Drug Administration will review therascreen® KRAS RGQ PCR Kit for use with Erbitux® (cetuximab), a metastatic colorectal cancer therapyPMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancerQIAGEN achieves milestones in Personalized Healthcare with innovative companion diagnostics; FDA decisions expected in 2012

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences

MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences | Biomarkers and Personalized Medicine | Scoop.it
MDxHealth's biomarker part of large pivotal colon cancer trial ...: MDxHealth is a leading molecular diagnostics...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Scientists make progress on early detection of resistance to colorectal cancer drugs

"Mutations in a gene called KRAS are causally associated with acquired resistance to targeted therapies for colorectal cancers (CRC), according to new findings..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Targeted Cancer Therapies Doomed to Fail? - MedPage Today

Targeted Cancer Therapies Doomed to Fail? - MedPage Today | Biomarkers and Personalized Medicine | Scoop.it

Great article reviewing the impact blood based gene mutation detection could have on treatment strategies for cancer therapy.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer?

Background: Macrophage inhibitory cytokine-1 (MIC-1/GDF15) mediates nonsteroidal anti-inflammatory drug (NSAID) protection from colonic polyps in mice and is linked to the development of colorectal carcinoma in humans.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Study Shows Epigenomics Biomarker Predicts Drug Resistance In Colorectal Cancer - NASDAQ

Study Shows Epigenomics Biomarker Predicts Drug Resistance In Colorectal Cancer - NASDAQ | Biomarkers and Personalized Medicine | Scoop.it
Study Shows Epigenomics Biomarker Predicts Drug Resistance In Colorectal CancerNASDAQPK) Thursday said a study published in the January edition of The New England Journal of Medicine demonstrates the potential of TFAP2E and other biomarkers identified...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

‘FRESH Science for Clinicians’: Combining EGFR and BRAF Inh... : Oncology Times

"Although the vast majority of melanoma patients with BRAF-mutant tumors respond to BRAF inhibitors, the same is not true for colon cancer patients with the mutation. One study reported that just 5% of colon cancer patients with BRAF-mutant tumors responded to the BRAF inhibitor vemurafenib. Now, data from a functional genomics screen may explain that paradox, researchers reported here at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

 

Remarkably, the data also suggest that combining an EGFR inhibitor with a BRAF inhibitor may dramatically improve responses in patients with BRAF-mutant colon cancer..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

MDxHealth's Biomarker Part of Large Pivotal Colon Cancer Trial Initiated by Exact Sciences | Benzinga

"MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that its licensing partner Exact Sciences Corp. (Nasdaq: EXAS) has initiated a large pivotal trial for Cologuard™, its non-invasive, stool-based DNA colon cancer screening test. Exact confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth's methylation specific PCR (MSP [FREE Stock Trend Analysis]) platform in Cologuard.

Exact's multi-center DeeP-C study (Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer) will generate data to support its planned PMA submission to the U.S. Food and Drug Administration (FDA) in 2012. The company began enrolling patients in the study on June 30, 2011. It is planning to qualify approximately 60 sites in the United States and Canada for the study. Those sites are expected to enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for colorectal cancer."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

New Insights on Who Should Take Erbitux for Colon Cancer – Health OMG!

New Insights on Who Should Take Erbitux for Colon Cancer – Health OMG! | Biomarkers and Personalized Medicine | Scoop.it
Contrary to previous research, some patients with KRAS gene mutation may benefit.
 
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

ECCO-ESMO: VEGF Blocker Boosts Survival in Colon Cancer (CME ...

The addition of aflibercept (VEGF Trap, Zaltrap) to standard chemotherapy was associated with about a six-week improvement in overall survival and a two-month increase in progression-free survival compared with ...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Blocking Effects of siRNA on VEGF Expression in Human Colorectal Cancer Cells | Colon and Rectal Cancer » Cancer Articles

Yin Y, Cao LY, Wu WQ, Li H, Jiang Y, Zhang HF. Department of Pathology, Anhui Medical University, Hefei 230032, Anhui Province, China.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion : Nature Genetics : Nature Publishing Group

Matthew Meyerson and colleagues report the whole-genome sequencing of primary colorectal tumors and matched adjacent non-tumor tissue from nine individuals with colorectal cancer.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Oncosurgical tactic: Unresectable Stage IV Colorectal Cancer | The EJCMO Blog - Oncology Hematology

Oncosurgical tactic: Unresectable Stage IV Colorectal Cancer | The EJCMO Blog - Oncology Hematology | Biomarkers and Personalized Medicine | Scoop.it
An oncosurgical approach in unresectable stage IV colorectal cancer; an update based on COIN, PRIME, NORDIC VII and OPUS trial data.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Activation of biomarker may improve survival among obese patients with colorectal cancer – Health News Article - Axis Media and Publishing Company - AxisMediaIndia.com

more...
No comment yet.